ReviewClinical and translational allergy2020
Allergen exposure chambers: implementation in clinical trials in allergen immunotherapy.
Review in Clinical and translational allergy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Recent advances in allergen immunotherapy.Chinese medical journal · 2026Review
- Causal Approaches to Disease Progression Analyses.Epidemiology (Cambridge, Mass.) · 2025Article
- Article
- A Modern Approach to Clinical Outcome Assessment in Allergy Management: Advantages of Allergen Exposure Chambers.Journal of clinical medicine · 2024Review
- Diagnostic Workup in IgE-Mediated Allergy to Asteraceae Weed Pollen and Herbal Medicine Products in Europe.Medicina (Kaunas, Lithuania) · 2024Review
- A high-dose, depigmented polymerized birch pollen extract for subcutaneous allergen immunotherapy has a favourable efficacy/safety ratio.Clinical and translational allergy · 2023Article
- Barrier-forming, drug-free nasal spray reduces allergic symptoms induced by house dust mite allergen.Clinical and translational allergy · 2023Article
- Birch-induced allergic rhinitis: Results of exposure during nasal allergen challenge, environmental chamber, and pollen season.The World Allergy Organization journal · 2023Article
- Validated allergen exposure chamber is plausible tool for the assessment of house dust mite-triggered allergic rhinitis.Allergy · 2023Article
- Allergen provocation tests in respiratory research: building on 50 years of experience.The European respiratory journal · 2022Review
- Total IgE in tears accurately reflects the severity and predicts the prognosis of seasonal allergic conjunctivitis.Clinical and translational allergy · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergen exposure chambers (AECs) have been developed for controlled allergen challenges of allergic patients mimicking natural exposure. As such, these facilities have been utilized e.g., for proof of concept, dose finding or the demonstration of onset of action and treatment effect sizes of antiallergic medication. Moreover, clinical effects of and immunological mechanisms in allergen immunotherapy (AIT) have been investigated in AECs. In Europe AIT products have to fulfill regulatory requirements for obtaining market authorization through Phase I to III clinical trials. Multiple Phase II (dose-range-finding or proof-of-concept) trials on AIT products have been performed in AECs. However, they are not accepted by regulatory bodies for pivotal (Phase III) trials and a more thorough technical and clinical validation is requested. Recently, a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI) has outlined unmet needs in further development of AECs. The following review aims to address some of these needs on the basis of recently published data in the first part, whereas the second part overviews published examples of most relevant Phase II trials in AIT performed in AEC facilities.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.